Chardan Capital Has Positive Outlook of TNYA FY2025 Earnings

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) – Chardan Capital raised their FY2025 earnings estimates for Tenaya Therapeutics in a report released on Monday, March 24th. Chardan Capital analyst Y. Livshits now expects that the company will earn ($0.71) per share for the year, up from their previous estimate of ($1.10). Chardan Capital currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($1.35) per share.

A number of other research analysts also recently issued reports on the stock. Morgan Stanley reduced their price objective on shares of Tenaya Therapeutics from $15.00 to $5.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 12th. Canaccord Genuity Group reduced their price target on shares of Tenaya Therapeutics from $18.00 to $6.00 and set a “buy” rating on the stock in a research report on Thursday, March 13th. Finally, HC Wainwright lowered their price objective on shares of Tenaya Therapeutics from $18.00 to $5.00 and set a “buy” rating for the company in a report on Tuesday, March 11th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $6.25.

Tenaya Therapeutics Stock Up 7.9 %

Shares of Tenaya Therapeutics stock opened at $0.69 on Thursday. The business has a 50 day moving average of $0.92 and a 200 day moving average of $1.70. Tenaya Therapeutics has a 52 week low of $0.39 and a 52 week high of $5.32. The company has a market cap of $60.59 million, a PE ratio of -0.48 and a beta of 2.83.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its quarterly earnings results on Monday, March 17th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04.

Insider Activity at Tenaya Therapeutics

In related news, major shareholder Group Gp Lp Column III acquired 35,714,284 shares of Tenaya Therapeutics stock in a transaction that occurred on Wednesday, March 5th. The stock was bought at an average price of $0.70 per share, with a total value of $24,999,998.80. Following the transaction, the insider now directly owns 49,313,559 shares in the company, valued at approximately $34,519,491.30. This represents a 262.62 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders sold a total of 19,621 shares of company stock valued at $10,595 in the last three months. Company insiders own 32.76% of the company’s stock.

Institutional Investors Weigh In On Tenaya Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Woodline Partners LP purchased a new position in shares of Tenaya Therapeutics in the 4th quarter worth about $28,000. Trustees of Columbia University in the City of New York bought a new stake in Tenaya Therapeutics during the 4th quarter valued at about $417,000. Nuveen Asset Management LLC raised its holdings in Tenaya Therapeutics by 25.2% in the fourth quarter. Nuveen Asset Management LLC now owns 345,192 shares of the company’s stock worth $494,000 after buying an additional 69,377 shares during the last quarter. Ground Swell Capital LLC bought a new position in shares of Tenaya Therapeutics in the fourth quarter worth approximately $32,000. Finally, Deutsche Bank AG grew its holdings in shares of Tenaya Therapeutics by 304.1% during the fourth quarter. Deutsche Bank AG now owns 129,319 shares of the company’s stock valued at $185,000 after buying an additional 97,318 shares during the last quarter. 90.54% of the stock is owned by hedge funds and other institutional investors.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.